SB 159 (2017): relative to qualifying medical conditions for the purposes of therapeutic cannabis.

Cite this page

Granite Record indexes the General Court’s record; it is not that record. Where a citation allows only one source, cite the General Court — every page here links to what it is drawn from. The date below is the day the page was read.

MLA
“SB 159 (2017): relative to qualifying medical conditions for the purposes of therapeutic cannabis.” Granite Record, https://graniterecord.org/bill/2017/sb159. Accessed 24 Oct. 2026.
APA
Granite Record. (n.d.). SB 159 (2017): relative to qualifying medical conditions for the purposes of therapeutic cannabis. Retrieved 24 Oct. 2026, from https://graniterecord.org/bill/2017/sb159
Chicago
Granite Record. “SB 159 (2017): relative to qualifying medical conditions for the purposes of therapeutic cannabis.” Accessed 24 Oct. 2026. https://graniterecord.org/bill/2017/sb159.
BibTeX
@misc{bill-2017-sb159, title = {SB 159 (2017): relative to qualifying medical conditions for the purposes of therapeutic cannabis.}, howpublished = {Granite Record}, url = {https://graniterecord.org/bill/2017/sb159}, note = {Accessed 24 Oct. 2026} }

SB 159 (2017)

relative to qualifying medical conditions for the purposes of therapeutic cannabis.

  • Status: Killed
  • Term: 2017-2018
  • House committee: Health, Human Services and Elderly Affairs
  • Senate committee: Health and Human Services
  • Subject: Public and Mental Health

The Story

It was introduced on January 19, 2017 and referred to the Senate Health and Human Services committee. The committee held a public hearing on March 20, 2017. The committee recommended that the Senate pass it. On March 29, 2017 the Senate voted to pass it on a voice vote and ordered it to a third reading. It crossed to the House and was referred to the House Health, Human Services and Elderly Affairs committee. The committee held a public hearing on April 19, 2017. The committee met in executive session on April 25, 2017 and May 23, 2017. The committee voted unanimously, 16–0, to recommend that the House kill it, and the report was placed on the consent calendar. On June 1, 2017 the House voted to kill it on a voice vote.

Sponsors

Hearings and Sessions

  • March 20, 2017, 9:00 AM: hearing, Senate Health and Human Services, LOB 101
  • April 19, 2017, 11:00 AM: public hearing, House Health, Human Services and Elderly Affairs, LOB 205
  • April 25, 2017, 9:30 AM: executive session, House Health, Human Services and Elderly Affairs, LOB 205
  • May 23, 2017, 11:15 AM: executive session, House Health, Human Services and Elderly Affairs, LOB 205

Votes

  • March 29, 2017, Senate: Ought to Pass — voice vote, passed
  • June 1, 2017, House: Inexpedient to Legislate — voice vote, passed

The Docket

  • January 19, 2017: Introduced 01/19/2017 and Referred to Health and Human Services
  • March 14, 2017: ==CANCELLED== Hearing: 03/14/2017, Room 101, LOB, 01:00 pm
  • March 20, 2017: Hearing: 03/20/2017, Room 101, LOB, 09:00 am
  • March 23, 2017: Introduced 03/23/2017 and referred to Health, Human Services and Elderly Affairs
  • March 29, 2017: Committee Report: Ought to Pass, 03/29/2017
  • March 29, 2017: Ought to Pass : MA, VV; OT3rdg; 03/29/2017
  • April 19, 2017: Public Hearing: 04/19/2017 11:00 AM LOB 205
  • April 25, 2017: Executive Session: 04/25/2017 09:30 AM LOB 205
  • May 23, 2017: Executive Session: 05/23/2017 11:15 AM LOB 205
  • June 1, 2017: Committee Report: Inexpedient to Legislate for 06/01/2017 (Vote 16-0; CC)
  • June 1, 2017: Inexpedient to Legislate: MA VV 06/01/2017

Laws It Would Change

Related Bills

  • HB 1309 (2016): adding post-traumatic stress disorder to qualifying medical conditions under therapeutic use of cannabis.
  • HB 1453 (2016): relative to qualifying medical conditions for purposes of therapeutic cannabis.
  • HB 158 (2017): adding opioid addiction to qualifying medical conditions under therapeutic use of cannabis.
  • HB 159 (2017): adding fibromyalgia to qualifying medical conditions under therapeutic use of cannabis.
  • HB 197 (2017): adding myelitis disorder or disease to the definition of "qualifying medical condition" for the use of cannabis for therapeutic purposes.

From the General Court